Rock Springs Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Rock Springs Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,000,000	Closed	-$24.4M	–	154
2021 Q2	$24.4M	Sell	1,000,000 -76,200	-7%	-$1.72M	0.48%	67
2021 Q1	$27.8M	Sell	1,076,200 -536,300	-33%	-$23.6M	0.61%	58
2020 Q4	$86.2M	Buy	1,612,500 +39,300	+2%	+$1.95M	1.83%	10
2020 Q3	$64.9M	Buy	1,573,200 +518,200	+49%	+$22.4M	1.65%	13
2020 Q2	$51.1M	Buy	1,055,000 +30,000	+3%	+$1.44M	1.4%	17
2020 Q1	$43.3M	Buy	1,025,000 +355,000	+53%	+$14.6M	1.79%	12
2019 Q4	$28.7M	Buy	670,000 +483,000	+258%	+$21M	0.91%	45
2019 Q3	$6.73M	Buy	+187,000	New	+$5.67M	0.27%	89
2017 Q4	–	Sell	-182,000	Closed	-$6.86M	–	146
2017 Q3	$6.86M	Buy	182,000 +8,000	+5%	+$260K	0.32%	90
2017 Q2	$4.85M	Buy	+174,000	New	+$5.19M	0.25%	101
2014 Q1	–	Sell	-31,418	Closed	-$785K	–	76
2013 Q4	$785K	Buy	+31,418	New	+$741K	0.28%	66

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Rock Springs Capital Management's ACAD Position: Q3 2021 in Review

Rock Springs Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2021, closing a stake of 1,000,000 shares — an estimated $24.4M sold.

Rock Springs Capital Management first reported a position in ACAD in Q4 2013 and held it in 11 quarters. The position peaked at $86.2M in Q4 2020. 237 funds tracked by Wall St. Rank hold ACAD as of Q3 2021.

Rock Springs Capital Management reported no remaining Acadia Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Rock Springs Capital Management sold 1,000,000 Acadia Pharmaceuticals shares in Q3 2021, an estimated $24.4M.
Rock Springs Capital Management first reported a position in Acadia Pharmaceuticals in Q4 2013 and held it in 11 quarters.
Rock Springs Capital Management's Acadia Pharmaceuticals position peaked at $86.2M in Q4 2020.
237 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2021.

Based on Rock Springs Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.